Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I M Jacobson

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|November 30, 1989
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trialG L Davis, L A Balart, E R Schiff, et al.
Clinical Therapeutics|March 1, 1994
Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact ProfileG L Davis, L A Balart, E R Schiff, et al.
The American Journal of Gastroenterology|April 24, 2001
Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon aloneA D Min, J L Jones, S Esposito, et al.
Journal of Viral Hepatitis|December 10, 2016
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirinS Alqahtani, R Ozaras, V Isakov, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2017
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3Z M Younossi, M Stepanova, I M Jacobson, et al.
Journal of Viral Hepatitis|November 4, 2014
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studiesM P Manns, M W Fried, S Zeuzem, et al.
The New England Journal of Medicine|August 2, 1990
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy GroupR P Perrillo, E R Schiff, G L Davis, et al.
Journal of Viral Hepatitis|October 31, 2013
The new paradigm of hepatitis C therapy: integration of oral therapies into best practicesN H Afdhal, S Zeuzem, R T Schooley, et al.
Journal of Viral Hepatitis|August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3S Pianko, S Zeuzem, W-L Chuang, et al.
Journal of Viral Hepatitis|March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirinG R Foster, S Zeuzem, S Pianko, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|November 30, 1989
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trialG L Davis, L A Balart, E R Schiff, et al.
Clinical Therapeutics|March 1, 1994
Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact ProfileG L Davis, L A Balart, E R Schiff, et al.
The American Journal of Gastroenterology|April 24, 2001
Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon aloneA D Min, J L Jones, S Esposito, et al.
Journal of Viral Hepatitis|December 10, 2016
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirinS Alqahtani, R Ozaras, V Isakov, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2017
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3Z M Younossi, M Stepanova, I M Jacobson, et al.
Journal of Viral Hepatitis|November 4, 2014
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studiesM P Manns, M W Fried, S Zeuzem, et al.
The New England Journal of Medicine|August 2, 1990
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy GroupR P Perrillo, E R Schiff, G L Davis, et al.
Journal of Viral Hepatitis|October 31, 2013
The new paradigm of hepatitis C therapy: integration of oral therapies into best practicesN H Afdhal, S Zeuzem, R T Schooley, et al.
Journal of Viral Hepatitis|August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3S Pianko, S Zeuzem, W-L Chuang, et al.
Journal of Viral Hepatitis|March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirinG R Foster, S Zeuzem, S Pianko, et al.
Pageof 5